2026-01-22 - Analysis Report
**Stock Review Report: AbbVie (ABBV)**

### 1. Company Overview
AbbVie is a research-based global biopharmaceutical company with a focus on developing and commercializing innovative therapies across various therapeutic areas.

### 2. Return Rate Comparison

* Cumulative return of review stock (ABBV): **177.76%**
* Cumulative return of comparison stock (S&P 500, VOO): **91.55%**
* Divergence (max: 135.40, min: -20.20, current: 82.20, relative divergence: 65.80%)

The review stock (ABBV) has shown a much higher cumulative return than the comparison stock (S&P 500, VOO), indicating a significant divergence. This may suggest that ABBV has performed exceptionally well compared to the broader market.

### 3. Analysis of Alpha, Beta, and Cap

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 50.0% | 16.0% | 46.0% | 1.0 | 162.9B |
| 2017-2019  | 42.0% | 21.6% | 24.0% | 1.1 | 156.5B |
| 2018-2020  | 4.0% | 21.6% | -17.0% | 0.8 | 189.4B |
| 2019-2021  | 61.0% | 20.5% | 18.0% | 0.7 | 239.3B |
| 2020-2022  | 66.0% | 18.5% | 68.0% | 0.6 | 285.6B |
| 2021-2023  | 45.0% | 18.5% | 44.0% | 0.4 | 273.9B |
| 2022-2024  | 37.0% | 18.9% | 18.0% | 0.3 | 314.1B |
| 2023-2025  | 99.0% | 18.9% | 37.0% | 0.3 | 403.8B |

### 4. Recent Stock Price Fluctuations

* Close: **$216.15**
* 5-day SMA: **$216.64**
* 20-day SMA: **$224.03**
* 60-day SMA: **$225.36**
* Recent market movement: **0.99%** up

### 5. RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence

* RSI: **36.31**
* PPO: **-0.53**
* Hybrid Signal: Buy ( **0%** cash)
* Risk Level: Medium (MRI **0.80**)
* Recent (20 days) relative divergence change: **-2.80** (-) worsening
* 7-day Rank change: **2** (+) rank up
* 7-day Dynamic Expected Return change: **0.60** (+) improving

### 6. Expected Return and Fluctuation Issue

* Expected Return (%): **40.20%**
* Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

### 7. Recent News & Significant Events

The recent news and significant events affecting AbbVie stock include:

* [2026-01-21] AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market - Finviz (news.google.com)
* [2026-01-21] Price Over Earnings Overview: AbbVie - AbbVie (NYSE:ABBV) - Benzinga (news.google.com)
* [2026-01-15] AbbVie (ABBV) Stock Dips While Market Gains: Key Facts - Yahoo Finance (news.google.com)
* [2026-01-18] Could Buying This Stock Today Pay Off Big Over the Next 5 Years? - The Motley Fool (news.google.com)
* [2026-01-21] Analysts Are Bullish on Top Healthcare Stocks: Dexcom (DXCM), AbbVie (ABBV) - The Globe and Mail (news.google.com)
* [2026-01-20] The Long-Term Investment Value of Eli Lilly, AbbVie, and Intuitive Surgical - NAI500 (news.google.com)

### 8. Analyst Opinions

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 245.22 / 289.00 / 184.00

### 9. Comprehensive Analysis (Summary of previous items, including news)

Based on the analysis, AbbVie (ABBV) has demonstrated exceptional growth and performance compared to the S&P 500. The company's alpha, beta, and capitalization data suggest a strong performance in various periods. The recent stock price fluctuations indicate a slight increase, and the RSI, PPO, and hybrid signal suggest a buy signal. The expected return and fluctuation issue also indicate a potential for growth. The recent news and significant events suggest positive developments for the company. Overall, the analyst consensus is positive, with a mean rating of 1.93 (~Buy) and a target price range of 245.22 to 289.00.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.